Clinical relevance and functional implications for human leucocyte antigen‐g expression in non‐small‐cell lung cancer
Authors:
Open Access
- 13 July 2009
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 14 (9) , 2318-2329
Abstract
HLA‐G has been documented both in establishment of anti‐tumour immune responses and in tumour evasion. To investigate the clinical relevance of HLA‐G in non‐small‐cell lung cancer (NSCLC), expression status and potential significance of HLA‐G in NSCLC were analysed. In this study, HLA‐G expression in 101 NSCLC primary lesions and plasma soluble HLA‐G (sHLA‐G) from 91 patients were analysed with immunohistochemistry and ELISA, respectively. Correlations between HLA‐G status and various clinical parameters including survival time were evaluated. Meanwhile, functional analysis of transfected cell surface HLA‐G expression and plasma sHLA‐G form NSCLC patients on natural killer (NK) cell cytolysis were performed. Data revealed that HLA‐G was expressed in 41.6% (42/101) NSCLC primary lesions, while undetectable in adjacent normal lung tissues. HLA‐G expression in NSCLC lesions was strongly correlated to disease stages (P= 0.002). Plasma sHLA‐G from NSCLC patients was markedly higher than that in normal controls (P= 0.004), which was significantly associated with the disease stages (I versus IV, P= 0.025; II versus IV, P= 0.029). Patient plasma sHLA‐G level (≥median, 32.0 U/ml) had a significantly shorter survival time (P= 0.044); however, no similar significance was observed for the lesion HLA‐G expression. In vitro data showed that both cell surface HLA‐G and patient plasma sHLA‐G could dramatically decrease the NK cell cytolysis. Our findings indicated that both lesion HLA‐G expression and plasma sHLA‐G in NSCLC is related to the disease stage and can exert immunosuppression to the NK cell cytolysis, indicating that HLA‐G could be a potential therapeutic target. Moreover, plasma sHLA‐G in NSCLC patients could be used as a prognosis factor for NSCLC.Keywords
This publication has 62 references indexed in Scilit:
- Beyond the increasing complexity of the immunomodulatory HLA-G moleculeBlood, 2008
- HLA-G: from biology to clinical benefitsTrends in Immunology, 2008
- Soluble HLA-G: Are they clinically relevant?Seminars in Cancer Biology, 2007
- Non‐classical major histocompatibility complex proteins as determinants of tumour immunosurveillanceEMBO Reports, 2007
- Detection of HLA-G5 secreting cellsHuman Immunology, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cellsHuman Immunology, 2000
- Identification of a Thymic Epithelial Cell Subset Sharing Expression of the Class Ib HLA-G Molecule with Fetal TrophoblastsJournal of Experimental Medicine, 1997
- Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens.Proceedings of the National Academy of Sciences of the United States of America, 1992
- A Class I Antigen, HLA-G, Expressed in Human TrophoblastsScience, 1990